Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 10, 2015, Pages 999-1024

  Chen, Xiao Wu ^a   He, Zhi Xu ^b   Zhou, Zhi Wei ^c   Yang, Tianxin ^d   Zhang, Xueji ^e   Yang, Yin Xue ^f   Duan, Wei ^g   Zhou, Shu Feng ^b,c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

^f NINGXIA MEDICAL UNIVERSITY   (China)

^g DEAKIN UNIVERSITY   (Australia)

Author keywords

Alogliptin; Anagliptin; Dipeptidyl peptidase 4 inhibitor; Gemigliptin; Linagliptin; Saxagliptin; Sitagliptin; Teneligliptin; Type 2 diabetes; Vildagliptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ANAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GEMIGLIPTIN; INCRETIN; LINAGLIPTIN; METFORMIN; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TENELIGLIPTIN; VILDAGLIPTIN;

ACUTE PANCREATITIS; ALLERGIC REACTION; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HEADACHE; HEALING IMPAIRMENT; HUMAN; HYPOGLYCEMIA; IMMUNE DYSREGULATION; KIDNEY FAILURE; LIVER FAILURE; MONOTHERAPY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RHINOPHARYNGITIS; RISK ASSESSMENT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; URINARY TRACT INFECTION; ANIMAL; DIABETES MELLITUS, TYPE 2; SAFETY;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; SAFETY;

EID: 84941558262     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12455     Document Type: Article

References (180)

1. Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes: A disease with increasing heterogeneity. Lancet 2014; 383: 1084-94.
2. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: Epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-40.
3. Inzucchi SE. Clinical practice. Diagnosis of diabetes. N. Engl. J. Med. 2012; 367: 542-50.
4. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. International Diabetes Federation, Brussels. 2013.
5. Centres for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Centres for Disease Control and Prevention, Atlanta, GA. 2014.
6. Chan JC, Zhang Y, Ning G. Diabetes in China: A societal solution for a personal challenge. Lancet Diabetes Endocrinol. 2014; 2: 969-79.
7. Holman RR. Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive. Nat. Rev. Endocrinol. 2013; 9: 67-8.
8. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: New and future developments in treatment. Lancet 2011; 378: 182-97.
9. McCarthy MI. Genomics, type 2 diabetes, and obesity. N. Engl. J. Med. 2010; 363: 2339-50.
10. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N. Engl. J. Med. 2012; 366: 1227-39.
11. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: From pathophysiology to prevention and management. Lancet 2011; 378: 169-81.
12. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: Clinical manifestations and current treatments. Lancet Neurol. 2012; 11: 521-34.
13. Mehanna A. Antidiabetic agents: Past, present and future. Future Med. Chem. 2013; 5: 411-30.
14. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: Dietary components and nutritional strategies. Lancet 2014; 383: 1999-2007.
15. 1c targets for type 2 diabetes: How many, ...how far!. Diabetes Res. Clin. Pract. 2012; 96: 414-15.
16. Ong KL, Cheung BM, Wong LY, Wat NM, Tan KC, Lam KS. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann. Epidemiol. 2008; 18: 222-9.
17. Rea D, Fulop V. Structure-function properties of prolyl oligopeptidase family enzymes. Cell Biochem. Biophys. 2006; 44: 349-65.
18. Gass J, Khosla C. Prolyl endopeptidases. Cell. Mol. Life Sci. 2007; 64: 345-55.
19. Szeltner Z, Polgar L. Structure, function and biological relevance of prolyl oligopeptidase. Curr. Protein Pept. Sci. 2008; 9: 96-107.
20. Edwards KL, Stapleton M, Weis J, Irons BK. An update in incretin-based therapy: A focus on glucagon-like peptide-1 receptor agonists. Diabetes Technol. Ther. 2012; 14: 951-67.
21. Stonehouse AH, Darsow T, Maggs DG. Incretin-based therapies. J Diabetes 2012; 4: 55-67.
22. Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease. Atherosclerosis 2013; 226: 305-14.
23. Darmoul D, Lacasa M, Chantret I, Swallow DM, Trugnan G. Isolation of a cDNA probe for the human intestinal dipeptidylpeptidase IV and assignment of the gene locus DPP4 to chromosome 2. Ann. Human Genet. 1990; 54: 191-7.
24. Darmoul D, Lacasa M, Baricault L et al. Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. J. Biol. Chem. 1992; 267: 4824-33.
25. Tanaka T, Camerini D, Seed B, et al. Cloning and functional expression of the T cell activation antigen CD26. J. Immunol. 1992; 149: 481-6.
26. Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol. Metab. 2013; 24: 85-91.
27. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J. Clin. Endocrinol. Metab. 2009; 94: 1843-52.
28. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: A parallel-group study. Lancet 2002; 359: 824-30.
29. Amblee A. Dulaglutide for the treatment of type 2 diabetes. Drugs Today 2014; 50: 277-89.
30. Sisson EM. Liraglutide: Clinical pharmacology and considerations for therapy. Pharmacotherapy 2011; 31: 896-911.
31. Neumiller JJ. Incretin pharmacology: A review of the incretin effect and current incretin-based therapies. Cardiovasc. Hematol. Agents Med. Chem. 2012; 10: 276-88.
32. Angeli FS, Shannon RP. Incretin-based therapies: Can we achieve glycemic control and cardioprotection? J. Endocrinol. 2014; 221: T17-30.
33. Forst T, Pfutzner A. Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus. Expert Opin. Pharmacother. 2013; 14: 2281-96.
34. Russell S. Incretin-based therapies for type 2 diabetes mellitus: A review of direct comparisons of efficacy, safety and patient satisfaction. Int. J. Clin. Pharm. 2013; 35: 159-72.
35. Rummey C, Metz G. Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Proteins 2007; 66: 160-71.
36. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005; 54: 2988-94.
37. Agrawal R, Bahare RS, Jain P, Dikshit SN, Ganguly S. Novel serine protease dipeptidyl peptidase IV inhibitor: Alogliptin. Mini Rev. Med. Chem. 2012; 12: 1345-58.
38. Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy-focus on alogliptin. Drug Des. Devel. Ther. 2013; 7: 989-1001.
39. Christopher R, Covington P, Davenport M et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin. Ther. 2008; 30: 513-27.
40. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin. Pharmacokinet. 2012; 51: 501-14.
41. Jarvis CI, Cabrera A, Charron D. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Ann. Pharmacother. 2013; 47: 1532-9.
42. Ndefo UA, Okoli O, Erowele G. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. Am. J. Health Syst. Pharm. 2014; 71: 103-9.
43. Cada DJ, Levien TL, Baker DE. Alogliptin. Hosp. Pharm. 2013; 48: 580-92.
44. Marino AB, Cole SW. Alogliptin: Safety, efficacy, and clinical implications. J. Pharm. Pract. 2015; 28: 99-106.
45. Seino Y, Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin. Pharmacother. 2014; 15: 851-63.
46. Dineen L, Law C, Scher R, Pyon E. Alogliptin (nesina) for adults with type-2 diabetes. P. T. 2014; 39: 186-202.
47. Said S, Nwosu AC, Mukherjee D, Hernandez GT. Alogliptin; A review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. Cardiovasc. Hematol. Disord. Drug Targets 2014; 14: 64-70.
48. Kutoh E, Kaneoka N, Hirate M. Alogliptin: A new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties. Endocr. Res. 2014; 40: 1-9.
49. Ceriello A, Sportiello L, Rafaniello C, Rossi F. DPP-4 inhibitors: Pharmacological differences and their clinical implications. Expert Opin. Drug Saf. 2014; 13 (Suppl. 1): 57-68.
50. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study G. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A multicentre, randomised, double-blind, placebo-controlled study. Int. J. Clin. Pract. 2009; 63: 46-55.
51. Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: A 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes. Metab. 2011; 13: 1088-96.
52. Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: A randomized, double-blind, 6-month study. Diabetes Obes. Metab. 2014; 16: 613-21.
53. Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care 2010; 33: 2406-8.
54. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Curr. Med. Res. Opin. 2009; 25: 2361-71.
55. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2012; 97: 1615-22.
56. Van Raalte DH, van Genugten RE, Eliasson B, et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes. Eur. J. Endocrinol. 2014; 170: 565-74.
57. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: A two-year study. Diabetes Obes. Metab. 2014; 16: 1239-46.
58. Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: A prospective, double-blind, randomized, 1-year study. Diabetes Obes. Metab. 2013; 15: 906-14.
59. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q, Alogliptin Study G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes. Metab. 2009; 11: 167-76.
60. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr. Med. Res. Opin. 2011; 27 (Suppl. 3): 21-9.
61. Takahara M, Shiraiwa T, Katakami N, Kaneto H, Matsuoka TA, Shimomura I. Efficacy of adding once- and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin. Endocr. J. 2014; 61: 447-56.
62. Kurozumi A, Okada Y, Mori H, Arao T, Tanaka Y. Efficacy of α-glucosidase inhibitors combined with dipeptidyl-peptidase-4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus by continuous glucose monitoring. J. Diabetes Investig. 2013; 4: 393-8.
63. Kusunoki Y, Katsuno T, Myojin M, et al. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. Endocr. J. 2013; 60: 431-9.
64. 1C without causing weight gain or increased hypoglycaemia. Diabetes Obes. Metab. 2009; 11: 1145-52.
65. Kaku K, Mori M, Kanoo T, Katou M, Seino Y. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opin. Pharmacother. 2014; 15: 2121-30.
66. Covington P, Christopher R, Davenport M et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin. Ther. 2008; 30: 499-512.
67. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: A randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31: 2315-17.
68. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr. Med. Res. Opin. 2011; 27: 1781-92.
69. Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic β-cells in prediabetic db/db mice. Diabetes Obes. Metab. 2010; 12: 224-33.
70. Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: A pooled analysis from phase 2 and 3 studies. J. Am. Geriatr. Soc. 2009; 57: 2011-19.
71. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes. Metab. 2010; 12: 648-58.
72. Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem. 2007; 50: 2297-300.
73. Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): Focus on drug-drug interactions. Clin. Pharmacokinet. 2010; 49: 573-88.
74. Davis TM. Dipeptidyl peptidase-4 inhibitors: Pharmacokinetics, efficacy, tolerability and safety in renal impairment. Diabetes Obes. Metab. 2014; 16: 891-9.
75. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: Similarities and differences. Drugs 2011; 71: 1441-67.
76. Karim A, Laurent A, Munsaka M, Wann E, Fleck P, Mekki Q. Coadministration of pioglitazone or glyburide and alogliptin: Pharmacokinetic drug interaction assessment in healthy participants. J. Clin. Pharmacol. 2009; 49: 1210-19.
77. White WB, Pratley R, Fleck P, et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes. Metab. 2013; 15: 668-73.
78. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 2013; 369: 1327-35.
79. Kato N, Oka M, Murase T, et al. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methyl pyrazolo[1, 5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg. Med. Chem. 2011; 19: 7221-7.
80. Tsubamoto Y, Goto M. Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 2013; 141: 339-49.
81. 14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. Xenobiotica 2013; 43: 432-42.
82. Jin SM, Park SW, Yoon KH, et al. Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes. Metab. 2015; 17: 511-15.
83. Yang HK, Min KW, Park SW, et al. A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes. Endocr. J. 2015; 62: 449-62.
84. Nishio S, Abe M, Ito H. Anagliptin in the treatment of type 2 diabetes: Safety, efficacy, and patient acceptability. Diabetes Metab. Syndr. Obes. 2015; 8: 163-71.
85. Kim SH, Lee SH, Yim HJ. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: First new anti-diabetic drug in the history of Korean pharmaceutical industry. Arch. Pharmacal Res. 2013; 36: 1185-8.
86. Lim KS, Kim JR, Choi YJ, et al. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. Clin. Ther. 2008; 30: 1817-30.
87. Lim KS, Cho JY, Kim BH, et al. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers. Br. J. Clin. Pharmacol. 2009; 68: 883-90.
88. Rhee EJ, Lee WY, Yoon KH. A multicentre, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. Diabetes Obes. Metab. 2010; 12: 1113-19.
89. Yang SJ, Min KW, Gupta SK, et al. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Diabetes Obes. Metab. 2013; 15: 410-16.
90. Rhee EJ, Lee WY, Min KW, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Obes. Metab. 2013; 15: 523-30.
91. 14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Xenobiotica 2014; 44: 522-30.
92. Choi HY, Noh YH, Kim YH, et al. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1, 000 mg (25/500 mg × 2 tablets) fixed dose combination tablet in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. 2014; 52: 381-91.
93. Noh YH, Lim HS, Jin SJ, et al. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: A crossover drug-drug interaction study in healthy male Korean volunteers. Clin. Ther. 2012; 34: 1182-94.
94. Kim SE, Yi S, Shin KH, et al. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 2012; 50: 17-23.
95. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin. Investig. Drugs 2010; 19: 133-40.
96. Tiwari A. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Curr. Opin. Investig. Drugs 2009; 10: 1091-104.
97. Scott LJ. Linagliptin: In type 2 diabetes mellitus. Drugs 2011; 71: 611-24.
98. Barnett AH. Linagliptin: A novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy. Adv. Ther. 2011; 28: 447-59.
99. Rendell M, Chrysant SG. Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Postgrad. Med. 2011; 123: 183-6.
100. Kalra S, Unnikrishnan AG, Agrawal N, Singh AK. Linagliptin and newer DPP-4 inhibitors: Newer uses and newer indications. Recent Pat. Endocr. Metab. Immune Drug Discov. 2011; 5: 197-202.
101. Ghatak SB, Patel DS, Shanker N, Srivastava A, Deshpande SS, Panchal SJ. Linagliptin: A novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus. Curr. Diabetes Rev. 2011; 7: 325-35.
102. Scheen AJ. Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation). Expert Opin. Drug Metab. Toxicol. 2011; 7: 1561-76.
103. Aletti R, Cheng-Lai A. Linagliptin: The newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Cardiol. Rev. 2012; 20: 45-51.
104. Forst T, Pfutzner A. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin. Pharmacother. 2012; 13: 101-10.
105. Singh-Franco D, McLaughlin-Middlekauff J, Elrod S, Harrington C. The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes. Metab. 2012; 14: 694-708.
106. Agrawal R, Jain P, Dikshit SN. Linagliptin: A novel methylxanthin based approved dipeptidyl peptidase-4 inhibitor. Curr. Drug Targets 2012; 13: 970-83.
107. Neumiller JJ, Setter SM. Review of linagliptin for the treatment of type 2 diabetes mellitus. Clin. Ther. 2012; 34: 993-1005.
108. Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin. Pharmacokinet. 2012; 51: 411-27.
109. Deeks ED. Linagliptin: A review of its use in the management of type 2 diabetes mellitus. Drugs 2012; 72: 1793-824.
110. Hoimark L, Laursen T, Rungby J. Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes. Diabetes Metab. Syndr. Obes. 2012; 5: 295-302.
111. Brown DX, Choudhury M, Evans M. Linagliptin as add-on therapy for type 2 diabetes - an overview. Drugs Today 2012; 48: 645-54.
112. Lajara R. Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes. Expert Opin. Pharmacother. 2012; 13: 2663-71.
113. Koliaki C, Doupis J. Linagliptin/Metformin fixed-dose combination treatment: A dual attack to type 2 diabetes pathophysiology. Adv. Ther. 2012; 29: 993-1004.
114. McGill JB. Linagliptin for type 2 diabetes mellitus: A review of the pivotal clinical trials. Ther. Adv. Endocrinol. Metab. 2012; 3: 113-24.
115. Haak T. Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia. Adv. Ther. 2012; 29: 1005-15.
116. Gallwitz B. Emerging DPP-4 inhibitors: Focus on linagliptin for type 2 diabetes. Diabetes Metab. Syndr. Obes. 2013; 6: 1-9.
117. Scheen AJ. Linagliptin plus metformin: A pharmacokinetic and pharmacodynamic evaluation. Expert Opin. Drug Metab. Toxicol. 2013; 9: 363-77.
118. Scheen AJ. Efficacy and safety of Jentadueto(R) (linagliptin plus metformin). Expert Opin. Drug Saf. 2013; 12: 275-89.
119. Maxwell LG, McFarland MS. Clinical utility and tolerability of linagliptin in diabetic patients. Drug Healthc. Patient Saf. 2013; 5: 67-78.
120. Guedes EP, Hohl A, de Melo TG, Lauand F. Linagliptin: Farmacology, efficacy and safety in type 2 diabetes treatment. Diabetol. Metab. Syndr. 2013; 5: 25.
121. Gallwitz B. Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors. Ther. Adv. Endocrinol. Metab. 2013; 4: 95-105.
122. Grunberger G. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin. Postgrad. Med. 2013; 125: 79-90.
123. von Websky K, Reichetzeder C, Hocher B. Linagliptin as add-on therapy to insulin for patients with type 2 diabetes. Vasc. Health Risk Manag. 2013; 9: 681-94.
124. Eckhardt M, Langkopf E, Mark M, et al. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylme thyl)-3, 7-dihydropurine-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 2007; 50: 6450-3.
125. Huttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J. Clin. Pharmacol. 2008; 48: 1171-8.
126. Heise T, Graefe-Mody EU, Huttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes. Metab. 2009; 11: 786-94.
127. Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: A randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes. Metab. 2012; 14: 348-57.
128. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Obes. Metab. 2011; 13: 258-67.
129. Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA. Evaluation of the potential for steady state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr. Med. Res. Opin. 2009; 25: 1963-72.
130. Taskinen MR, Rosenstock J, Tamminen I et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes. Metab. 2011; 13: 65-74.
131. Forst T, Uhlig-Laske B, Ring A et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet. Med. 2010; 27: 1409-19.
132. Gallwitz B, Rosenstock J, Rauch T, et al. 2-Year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, non-inferiority trial. Lancet 2012; 380: 475-83.
133. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes. Metab. 2011; 13: 653-61.
134. Gomis R, Owens DR, Taskinen MR, et al. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: Up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. Int. J. Clin. Pract. 2012; 66: 731-40.
135. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24-week randomized study. Diabetic Med. 2011; 28: 1352-61.
136. Graefe-Mody U, Giessmann T, Ring A, Iovino M, Woerle HJ. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin. Ther. 2011; 33: 1096-103.
137. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab. Dispos. 2010; 38: 667-78.
138. Fuchs H, Tillement JP, Urien S, Greischel A, Roth W. Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J. Pharm. Pharmacol. 2009; 61: 55-62.
139. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes. Metab. 2011; 13: 939-46.
140. McGill JB, Sloan L, Newman J, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: A 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care 2013; 36: 237-44.
141. Graefe-Mody U, Rose P, Retlich S, et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br. J. Clin. Pharmacol. 2012; 74: 75-85.
142. Schernthaner G, Barnett AH, Emser A, et al. Safety and tolerability of linagliptin: A pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2012; 14: 470-8.
143. Scheen AJ. A review of gliptins in 2011. Expert Opin. Pharmacother. 2012; 13: 81-99.
144. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc. Diabetol. 2012; 11: 3.
145. Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int. J. Cardiol. 2013; 167: 87-93.
146. Ring A, Port A, Graefe-Mody EU, Revollo I, Iovino M, Dugi KA. The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses. Br. J. Clin. Pharmacol. 2011; 72: 39-50.
147. Friedrich C, Port A, Ring A, et al. Effect of multiple oral doses of linagliptin on the steady state pharmacokinetics of a combination oral contraceptive in healthy female adults: An open-label, two-period, fixed-sequence, multiple-dose study. Clin. Drug Investig. 2011; 31: 643-53.
148. Friedrich C, Ring A, Brand T, Sennewald R, Graefe-Mody EU, Woerle HJ. Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur. J. Drug Metab. Pharmacokinet. 2011; 36: 17-24.
149. Graefe-Mody EU, Brand T, Ring A, et al. Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 2011; 49: 300-10.
150. Graefe-Mody U, Rose P, Ring A, Zander K, Iovino M, Woerle HJ. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Drug Metab. Pharmacokinet. 2011; 26: 123-9.
151. Graefe-Mody EU, Jungnik A, Ring A, Woerle HJ, Dugi KA. Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 2010; 48: 652-61.
152. Graefe-Mody U, Huettner S, Stahle H, Ring A, Dugi KA. Effect of linagliptin (BI 1356) on the steady state pharmacokinetics of simvastatin. Int. J. Clin. Pharmacol. Ther. 2010; 48: 367-74.
153. Nowicki M, Rychlik I, Haller H et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: A randomised controlled 52-week efficacy and safety study. Int. J. Clin. Pract. 2011; 65: 1230-9.
154. Hirshberg B, Parker A, Edelberg H, Donovan M, Iqbal N. Safety of saxagliptin: Events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 2014; 30: 556-69.
155. Dave DJ. Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. J. Pharmacol. Pharmacother. 2011; 2: 230-5.
156. Neumiller JJ, Campbell RK. Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. Am. J. Health Syst. Pharm. 2010; 67: 1515-25.
157. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013; 369: 1317-26.
158. Subbarayan S, Kipnes M. Sitagliptin: A review. Expert Opin. Pharmacother. 2011; 12: 1613-22.
159. McFarland MS, Markley BM, Zhang P, Hudson JQ. Evaluation of Modification of Diet in Renal Disease Study and Cockcroft-Gault equations for sitagliptin dosing. J. Nephrol. 2012; 25: 515-22.
160. Eligar VS, Bain SC. A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment. Drug Des. Devel. Ther. 2013; 7: 893-903.
161. Round EM, Engel SS, Golm GT, Davies MJ, Kaufman KD, Goldstein BJ. Safety of sitagliptin in elderly patients with type 2 diabetes: A pooled analysis of 25 clinical studies. Drugs Aging 2014; 31: 203-14.
162. Lee M, Rhee MK. Sitagliptin for Type 2 diabetes: A 2015 update. Expert Rev. Cardiovasc. Ther. 2015; 13: 597-610.
163. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study. JAMA Intern. Med. 2013; 173: 534-9.
164. Bethel MA, Green JB, Milton J, et al. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes. Metab. 2015; 17: 395-402.
165. Yoshida T, Akahoshi F, Sakashita H, et al. Discovery and preclinical profile of teneligliptin (3-[(2S, 4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-y lcarbonyl]thiazolidine): A highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. 2012; 20: 5705-19.
166. Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2013; 15: 810-18.
167. Kishimoto M. Teneligliptin: A DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab. Syndr. Obes. 2013; 6: 187-95.
168. Goda M, Kadowaki T. Teneligliptin for the treatment of type 2 diabetes. Drugs Today 2013; 49: 615-29.
169. Nakamaru Y, Hayashi Y, Ikegawa R, et al. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica 2014; 44: 242-53.
170. Brandt I, Joossens J, Chen X, et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem. Pharmacol. 2005; 70: 134-43.
171. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J. Med. Chem. 2003; 46: 2774-89.
172. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 2004; 89: 2078-84.
173. Zhang C, Feng Y, Qu S, et al. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc. Res. 2011; 90: 538-45.
174. He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin. Pharmacokinet. 2012; 51: 147-62.
175. He YL, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin. Pharmacokinet. 2007; 46: 577-88.
176. He YL, Yamaguchi M, Ito H, Terao S, Sekiguchi K. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes. Int. J. Clin. Pharmacol. Ther. 2010; 48: 582-95.
177. Henness S, Keam SJ. Vildagliptin. Drugs 2006; 66: 1989-2001; discussion 2-4.
178. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial. Diabetes Obes. Metab. 2011; 13: 947-54.
179. Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes. Metab. 2012; 14: 1032-9.
180. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: A systematic review and meta-analysis. Diabetologia 2013; 56: 696-708.